AGA recommends fecal calprotectin, lactoferrin for screening for inflammatory bowel disease
FRIDAY, Sept. 27, 2019 (HealthDay News) — In new American Gastroenterological Association (AGA) clinical practice guidelines, published in the September issue of Gastroenterology, recommendations are presented for laboratory evaluation of chronic watery diarrhea.
Walter Smalley, M.D., M.P.H., from the Vanderbilt University School of Medicine in Nashville, Tennessee, and colleagues developed recommendations for the evaluation of immunocompetent patients with watery diarrhea of at least four weeks’ duration.
The AGA recommends use of either fecal calprotectin or fecal lactoferrin for screening for inflammatory bowel disease in patients presenting with chronic diarrhea. Erythrocyte sedimentation rate or C-reactive protein should not be used for inflammatory bowel disease screening in patients presenting with chronic diarrhea. The AGA recommends testing for Giardia in patients with chronic diarrhea. Testing for ova and parasites is not recommended for patients presenting with chronic diarrhea with no travel history to, or recent immigration from, high-risk areas. The AGA suggests testing for celiac disease with immunoglobulin A (IgA) tissue transglutaminase and, in the setting of IgA deficiency, providing a second test for celiac disease. Bile acid diarrhea should be tested for in chronic diarrhea. The AGA makes no recommendation for the use of currently available serologic tests for irritable bowel syndrome diagnosis in patients presenting with watery diarrhea.
“The AGA guideline on evaluation of chronic diarrhea is intended to reduce practice variation and promote high-quality and high-value care for this patient population” Smalley said in a statement.
Copyright © 2019 HealthDay. All rights reserved.
